52.17

0.56% 0.29

Moonlake Immunotherapeutics (MLTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché MLTX Giù? Forum Previsione

Precedente Chiudi:

$51.88

Aprire:

$51.71

Volume 24 ore:

190.98K

Relative Volume:

0.68

Capitalizzazione di mercato:

$3.29B

Reddito:

Utile/perdita netta:

$-80.77M

Rapporto P/E:

-44.62

EPS:

-1.1692

Flusso di cassa netto:

$-80.80M

1 W Prestazione:

+1.62%

1M Prestazione:

+4.72%

6M Prestazione:

+32.11%

1 anno Prestazione:

-9.32%

Intervallo 1D:

$50.21

$54.10

Intervallo di 1 settimana:

$50.21

$58.26

Portata 52W:

$37.55

$64.98

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Nome

Moonlake Immunotherapeutics

Settore

Healthcare (1176)

Industria

Biotechnology (673)

Telefono

41 41 510 8022

Indirizzo

DORFSTRASSE 29, ZUG

Dipendente

Cinguettio

Prossima data di guadagno

2024-11-12

Ultimi documenti SEC

MLTX's Discussions on Twitter

Confronta MLTX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
MLTX Moonlake Immunotherapeutics	52.17	3.29B	0	-80.77M	-80.80M	-1.27
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-11-05	Ripresa	Wedbush	Outperform
2024-08-26	Downgrade	Wolfe Research	Outperform → Peer Perform
2024-06-25	Iniziato	Oppenheimer	Outperform
2024-04-02	Iniziato	Goldman	Neutral
2024-02-15	Iniziato	Wolfe Research	Outperform
2023-12-08	Iniziato	Citigroup	Buy
2023-11-02	Iniziato	Stifel	Buy
2023-09-14	Downgrade	Bryan Garnier	Buy → Neutral
2023-08-31	Iniziato	Needham	Buy
2023-06-15	Iniziato	Barclays	Equal Weight
2023-05-01	Iniziato	Guggenheim	Buy
2023-03-22	Iniziato	Wedbush	Outperform
2023-03-09	Iniziato	BTIG Research	Buy
2023-02-14	Iniziato	Cantor Fitzgerald	Overweight
2023-02-02	Iniziato	Bryan Garnier	Buy
2022-11-11	Iniziato	Jefferies	Buy
2022-08-25	Iniziato	SVB Leerink	Outperform
2022-07-21	Iniziato	H.C. Wainwright	Buy
2022-07-07	Iniziato	Cowen	Outperform

Mostra tutto

Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie

Dec 20, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Down 3.2%What's Next? - MarketBeat

Dec 20, 2024

Dec 18, 2024

MoonLake Immunotherapeutics announces board change, incentive plan - Investing.com

Dec 18, 2024

MoonLake Immunotherapeutics Announces Board Changes and Incentives - TipRanks

Dec 18, 2024

MoonLake Immunotherapeutics announces board change, incentive plan By Investing.com - Investing.com UK

Dec 18, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Dec 18, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Dec 18, 2024

Dec 17, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 7.9%Here's What Happened - MarketBeat

Dec 17, 2024

Dec 16, 2024

We're Not Very Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Rate - Simply Wall St

Dec 16, 2024

Wellington Management Group LLP Cuts Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Dec 16, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Dec 16, 2024

Dec 15, 2024

Trading (MLTX) With Integrated Risk Controls - Stock Traders Daily

Dec 15, 2024

Dec 14, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 5.6%What's Next? - MarketBeat

Dec 14, 2024

Dec 13, 2024

MoonLake Immunotherapeutics' SWOT analysis: stock outlook amid HS market potential - Investing.com

Dec 13, 2024

Dec 12, 2024

Clear Street sets $108 target on Moonlake Immunotherapeutics stock By Investing.com - Investing.com UK

Dec 12, 2024

Clear Street sets $108 target on Moonlake Immunotherapeutics stock - Investing.com

Dec 12, 2024

Dec 10, 2024

MoonLake Immunotherapeutics Reports Q3 2024 Financial Results - MSN

Dec 10, 2024

Dec 06, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Acquired by The Manufacturers Life Insurance Company - Defense World

Dec 06, 2024

Dec 05, 2024

When (MLTX) Moves Investors should Listen - Stock Traders Daily

Dec 05, 2024

Dec 04, 2024

Erste Asset Management GmbH Invests $741,000 in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Dec 04, 2024

Dec 02, 2024

Fmr LLC Purchases 1,306,215 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Dec 02, 2024

Nov 25, 2024

Westfield Capital Management Co. LP Boosts Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Nov 25, 2024

Nov 24, 2024

(MLTX) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 24, 2024

Nov 23, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $79.00 Consensus PT from Brokerages - MarketBeat

Nov 23, 2024

Nov 21, 2024

MoonLake Immunotherapeutics: A Somewhat Complicated Story (NASDAQ:MLTX) - Seeking Alpha

Nov 21, 2024

Victory Capital Management Inc. Has $10.98 Million Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Nov 21, 2024

Nov 19, 2024

MoonLake Immunotherapeutics Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 19, 2024

Nov 18, 2024

MoonLake Immunotherapeutics management to meet with Oppenheimer - TipRanks

Nov 18, 2024

Nov 14, 2024